ClinicalTrials.gg
TerminatedNCT05354362MATCHUpdated Mar 17, 2023

A Study of ATG-010 in Combination With ATG-008 in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

A Phase 1 interventional study of ATG-010 and ATG-008 in Relapsed/Refractory Diffuse Large B-cell Lymphoma, sponsored by Antengene Corporation. Terminated at 6 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-17.

Sponsored by Antengene Corporation · Phase 1, Interventional, and Treatment

Why this study was terminated
Based on the adjustment of clinical research and development strategy,sponsor decided to terminate the study

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing selinexor in Lymphoma, Large B-Cell, Diffuse — 1 open to participants now, 4 under way, 1 of them phase 3. selinexor · Lymphoma, Large B-Cell, Diffuse.

Enrollment
11th of 11
7 · median 54
Started
2022
with 1 other
Phase 1
4 of 11
none open now
Registered
9th of 11
by date
Lead sponsor
3 of 11
Antengene Corporation

Among the 11 studies testing selinexor in Lymphoma, Large B-Cell, Diffuse, this one is the 11th largest by enrollment, is one of 2 that started in 2022, is one of 4 in phase 1, and was the 9th registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

1 of the 11 studies testing selinexor in Lymphoma, Large B-Cell, Diffuse is open now. Recruiting first, the newest first:

About selinexor

selinexor: first FDA approval 2019 (XPOVIO), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing selinexor in Lymphoma, Large B-Cell, Diffuse, or all of them as a file.
02

Study summary

This is an Open label, Phase Ⅰb Study of ATG-010 in Combination With ATG-008 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)

Read the detailed description

This is a multi-center, open label, phase 1 study conducted in RR DLBCL patients. The MTD and/or RP2D of study treatment, ATG-010 in combination with ATG-008, will be selected using BOIN design for the dose escalation phase. Additional patients will be enrolled as an expansion cohort after MTD and/or RP2D is determined.

03

Conditions studied

  • Relapsed/Refractory Diffuse Large B-cell Lymphoma

Keywords

  • Lymphoma, Hodgkin's lymphoma , non-Hodgkin's lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years old.
  2. Performance score of ≤2.
  3. Estimated of >3 months.
  4. Previously treated, confirmed DLBCL
  5. Patients must have received at least 2 but no more than 5 previous systemic regimens (for non-DH/TH, non-DE DLBCL and DLBCL not transformed from FL or CLL), or at least 1 but no more than 5 previous systemic regimens (for DH/TH, DE DLBCL, and DLBCL transformed from FL or CLL) for the treatment of their DLBCL.

    1. Prior stem cell transplantation is allowed; induction, consolidation, stem cell collection, preparative regimen and transplantation ± maintenance are considered a single .
    2. Salvage chemoimmunotherapy followed by stem cell transplantation will be considered as 1 line of therapy.
    3. Any maintenance therapy will not be counted as a separate line of systemic therapy.
    4. Radiation with curative intent for localized DLBCL will not be counted as 1 line of therapy
  6. Documented radiographic evidence of progressive DLBCL of the last line (or DLBCL) prior to the first dosing.

Exclusion criteria

Exclusion Criteria:

  1. Female patients who are pregnant or lactating
  2. DLBCL with mucosa-associated lymphoid tissue [MALT] lymphoma, or primary mediastinal (thymic) large B-cell lymphoma (PMBL)
  3. Known central nervous system lymphoma or meningeal involvement (for dose expansion phase, patients with stable CNS disease could be considered).
  4. Patients eligible for high-dose chemotherapy with stem cell transplantation rescue (the Investigator must provide detailed documentation for ineligibility)
  5. Use of any standard or experimental anti-DLBCL therapy (including radiation, chemotherapy, immunotherapy, radio-immunotherapy, or any other anticancer therapy) \<21 days prior to Cycle 1 Day 1.
  6. Autologous stem cell transplant (SCT) \<6 months or prior allogeneic SCT, or CAR-T cell infusion \<6 months prior to Cycle 1.
  7. Major surgery within 4 weeks of the first dose of study treatment.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    ATG-010 and ATG-008

    ATG-010 and ATG-008 should be taken 6 hours apart on a PK sampling day

    Combination Product: ATG-010 and ATG-008

Interventions

  • Combination productATG-010 and ATG-008

    Drug pages: Selinexor · CC-223

    Patients enrolled will receive consecutive daily treatment at assigned dose level. The starting dose of ATG-010 at the dose escalation phase will be 60 mg QW, which could be escalated to 80 mg QW, 100 mg QW, 60 mg BIW. In case 60 mg QW of ATG-010 with any dose of ATG-008 is NOT tolerable, 40 mg QW ATG-010 could be explored. The starting dose of ATG-008 will be 15 mg QD, which could be escalated to 20 mg QD, with maximum of 30 mg QD. SRC will be consulted before each dose escalation starts.

06

What researchers measure

Primary outcomes

  1. MTD

    Maximum Tolerated Dose

    Time frame: the last patient on study has completed 12 months of follow-up

  2. RP2D

    Recommended Phase 2 Dose

    Time frame: the last patient on study has completed 12 months of follow-up

Secondary outcomes

  1. ORR

    Overall Response Rate

    Time frame: the last patient on study has completed 12 months of follow-up

  2. PFS

    Progression Free Survival

    Time frame: the last patient on study has completed 12 months of follow-up

  3. DOR

    Duration of Response

    Time frame: the last patient on study has completed 12 months of follow-up

  4. OS

    Overall Survival

    Time frame: the last patient on study has completed 12 months of follow-up

  5. TTR

    Time To Response

    Time frame: the last patient on study has completed 12 months of follow-up

  6. TTP

    Time To Progression

    Time frame: the last patient on study has completed 12 months of follow-up

07

Study locations

6 sites
  • Chongqing Cancer Hospital
    Chongqing, Chongqing 400030, China
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong 510060, China
  • Guangzhou First People's Hospital
    Guangzhou, Guangdong 510180, China
  • Hubei Cancer Hospital
    Wuhan, Hubei 430079, China
  • Hunan Cancer Hospital
    Changsha, Hunan 410029, China
  • The first Affiliated Hospital of China medical University
    Shenyang, Liaoning 110001, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2022 to primary completion in Feb 2023, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2022
First posted
Apr 29, 2022
StartActual
Mar 2, 2022
Primary completionActual
Feb 6, 2023
CompletionActual
Feb 8, 2023
Last update
Mar 17, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05354362
Lead sponsor
Antengene Corporation
Responsible party
Sponsor
First posted
Apr 29, 2022
Start date
Mar 2, 2022
Primary completion
Feb 6, 2023
Completion
Feb 8, 2023
Last update
Mar 17, 2023

Study contacts

Yang Yu
study director · Medical Monitor

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Selinexor · CC-223

Start the discussion